Adiposity and Endothelin Receptor Function
| Status: | Recruiting |
|---|---|
| Conditions: | High Blood Pressure (Hypertension) |
| Therapuetic Areas: | Cardiology / Vascular Diseases |
| Healthy: | No |
| Age Range: | 18 - 40 |
| Updated: | 7/14/2018 |
| Start Date: | May 21, 2018 |
| End Date: | June 2021 |
| Contact: | Ryan Harris, PhD, CES |
| Email: | ryharris@augusta.edu |
| Phone: | 706-721-5998 |
Elevated levels of ET-1 have been implicated in cardiovascular disease and some forms of
hypertension. Due to the strong, positive correlation between obesity and hypertension, the
present study will explore the contribution of adiposity in ETB receptor function and aim to
elucidate if ETB receptor dysfunction is a major contributor to hypertension in obesity.
hypertension. Due to the strong, positive correlation between obesity and hypertension, the
present study will explore the contribution of adiposity in ETB receptor function and aim to
elucidate if ETB receptor dysfunction is a major contributor to hypertension in obesity.
The proposed study is designed to investigate the influence of adiposity on ETB receptor
function and subsequent vascular responses. The combination of ET-1, ET-3, and the respective
ETA and ETB receptor antagonists will be used to provide insight into the mechanisms of ETB
receptor dysfunction in the presence of adiposity. Previous studies have revealed elevations
in circulating ET-1 in obese individuals; therefore, we predict that obese subjects will
exhibit 1) ETB receptor dysfuncton compared to lean subjects and 2) an improvement in ETB
receptor dysfunction following treatment with Candesartan.
function and subsequent vascular responses. The combination of ET-1, ET-3, and the respective
ETA and ETB receptor antagonists will be used to provide insight into the mechanisms of ETB
receptor dysfunction in the presence of adiposity. Previous studies have revealed elevations
in circulating ET-1 in obese individuals; therefore, we predict that obese subjects will
exhibit 1) ETB receptor dysfuncton compared to lean subjects and 2) an improvement in ETB
receptor dysfunction following treatment with Candesartan.
Inclusion Criteria:
• If you are an adult between the ages of 18-40 year old
Exclusion Criteria:
- Evidence of cardiovascular, pulmonary, renal, hepatic, cerebral, or metabolic disease
- Evidence of pregnancy
- Using medications that affect vascular tone (i.e., nitrates, etc.)
- Use of any anticoagulants (i.e. aspirin)
- Anemia
- If you are postmenopausal
- If you have uncontrolled hypertension (treated resting SBP >140 mm Hg or DBP >90 mm
Hg)
We found this trial at
1
site
1441-1447 Walton Way
Augusta, Georgia 30912
Augusta, Georgia 30912
Phone: 706-721-5483
Click here to add this to my saved trials
